Migraine is a very common disease having a strong impact on the quality of life of patients. The cause of the trigger is variable and often difficult to identify, available prophylactic treatments have variable efficacy and are not free of side-effects.

All migraine patients worldwide are waiting for a “prophylactic” treatment which can reduce at least the intensity & frequency of migraine attacks without inducing side-effects. This should help minimize the fear of the next attack & accept the attack as “tolerable”.

MIGSPRAY is a new generation of multi-target treatment, conceived after 20-years of R&D, totally safe, effective in at least 60% patients, relatively inexpensive,  & quick-acting, which is directed not to treat migraine attacks but just to make migraine attacks less frequent and tolerable. This polymeric technology has already shown its extraordinary efficacy & safety to treat other multi-factorial protein-induced diseases such as allergy, asthma, viral infections, & chronic wounds. Big pharma companies like Sanofi have already licenced a few of the polymeric treatments for worldwide launch.